| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02125500 | Viral Hepatitis C|HIV | Drug: Sofosbuvir/Ledipasvir fixed dose | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | Phase 2 | 2014-09-01 | 2016-01-04 |
| NCT02478229 | Hepatitis C Viral Infection | Drug: Sofosbuvir (SOF) and Ledipasvir (LDV) | University Health Network, Toronto | Phase 3 | 2015-06-01 | 2016-08-04 |
| NCT02638233 | Chronic Hepatitis C | Drug: Sofosbuvir 400mg / Ledipasvir 90 mg (FDC) | Wilhelminenspital Vienna|Gilead Sciences | Phase 4 | 2015-09-01 | 2015-12-18 |
| NCT02705534 | Hepatitis C|Cirrhosis | Drug: Sofosbuvir|Drug: Ledipasvir|Drug: Ribavirin | Tehran University of Medical Sciences|Bakhtar Bioshimi Co | Phase 3 | 2016-09-01 | 2016-07-03 |
| NCT02683005 | Hepatitis C|Pregnancy | Drug: ledipasvir/sofosbuvir | University of Pittsburgh|Gilead Sciences|University of Nebraska | Phase 1 | 2016-09-01 | 2016-11-17 |
| NCT02836925 | Indolent B-cell Lymphoma|Hepatitis C | Drug: Sofosbuvir+Ledipasvir|Drug: Sofosbuvir+Ribavirin|Drug: Sofosbuvir+Ledipasvir+Ribavirin | Fondazione Italiana Linfomi ONLUS | Phase 2 | 2016-03-01 | 2016-09-20 |
| NCT02421211 | Hepatitis C, Chronic | Drug: Simeprevir (SMV)|Drug: Ledipasvir (LDV)|Drug: Sofosbuvir (SOF) | Janssen Sciences Ireland UC | Phase 2 | 2015-05-01 | 2016-11-07 |
| NCT03061032 | Hepatitis C | Drug: Sofosbuvir/Ledipasvir 12W|Drug: Sofosbuvir/Ledipasvir plus Ribavirin 12W|Drug: Sofosbuvir/Ledipasvir 24W|Drug: Sofosbuvir/Ledipasvir plus Ribavirin 24W | Iran Hepatitis Network|Baqiyatallah Research Center for Gastroenterology and Liver Diseases | Phase 3 | 2017-03-01 | 2017-02-17 |
| NCT01924949 | Hepatitis C | Drug: LDV/SOF | Gilead Sciences | Phase 2 | 2013-07-01 | 2015-05-13 |
| NCT02405013 | Hepatitis C|HIV Infection | Drug: Sofosbuvir|Drug: Ribavirin|Drug: Sofosbuvir|Drug: Ledipasvir | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | Phase 2 | 2015-10-01 | 2017-01-11 |
| NCT02472886 | Hepatitis C Infection | Drug: LDV/SOF|Drug: RBV | Gilead Sciences | Phase 3 | 2015-06-01 | 2016-07-05 |
| NCT02301936 | Hepatitis C Virus Infection | Drug: LDV/SOF | Gilead Sciences | Phase 2 | 2015-03-01 | 2016-04-26 |
| NCT02350569 | Hepatitis C Virus Infection | Drug: LDV/SOF | Gilead Sciences | Phase 2 | 2015-05-01 | 2016-04-26 |
| NCT02480387 | Treatment of Hepatitis C | Drug: Ledipasvir/Sofosbuvir FDC | Peter J. Ruane, M.D., Inc. | Phase 2 | 2015-05-01 | 2016-07-19 |
| NCT02600351 | Hepatitis C Virus Infection | Drug: LDV/SOF|Drug: RBV | Gilead Sciences | Phase 3 | 2015-11-01 | 2016-07-01 |
| NCT01984294 | Chronic HCV Infection | Drug: LDV/SOF|Drug: RBV|Drug: GS-9669 | Gilead Sciences | Phase 2 | 2013-10-01 | 2015-04-30 |
| NCT02251717 | Hepatitis C Virus Infection | Drug: LDV/SOF | Gilead Sciences | Phase 2 | 2014-10-01 | 2016-07-15 |
| NCT03005210 | Healthy | Drug: Magicbuvir Plus|Drug: Harvoni (fist dose)|Drug: Harvoni (second dose) | Genuine Research Center, Egypt|Magic Pharma, Egypt | Phase 1 | 2016-11-01 | 2016-12-28 |
| NCT02487030 | Hepatitis C Virus Infection | Drug: LDV/SOF|Drug: RBV | Gilead Sciences | Phase 3 | 2015-09-07 | 2017-02-21 |
| NCT02413593 | Hepatitis C Virus Infection | Drug: LDV/SOF|Drug: RBV | Gilead Sciences | Phase 2 | 2015-04-01 | 2016-12-22 |
